ehealth radio network
Plus Therapeutics: Gliblastoma, Rhenium NanoLiposome, and Harnessing the Power of Radiation Therapy

Plus Therapeutics: Gliblastoma, Rhenium NanoLiposome, and Harnessing the Power of Radiation Therapy

July 15, 2021

 

Dr_Mark_Hedrick8ef5z.png

 

Dr. Marc Hedrick, President and CEO at Plus Therapeutics which is a clinical-stage pharmaceutical company focused on making a positive impact on patients’ lives and adding value to the healthcare system joins eHealth Radio and the Cancer Information and Health News Channels.


Listen to interview with host Eric Michaels and guest Dr. Marc Hedrick discuss the following:

  1. What is Plus Therapeutics, and what is its mission?
  2. Tell us about your background and what brought you to Plus Therapeutics?
  3. What is Rhenium NanoLiposome (RNL™) and how is it delivered to cancerous brain tumors?
  4. How could RNL help advance current treatment options for GBM and why is this important for patients?
  5. Do you think most people understand radiation and its potential benefits as a cancer therapy?
  6. What do you think is the most common misconception that people hold about radiation as a cancer treatment?
  7. What’s next Plus Therapeutics? Is Plus developing other investigational candidates as part of its broader pipeline?

Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.

 

PLUS-06-e1559589501420.jpg

 

Website: plustherapeutics.com

Social Media Links:
Facebook: facebook.com/plustherapeutics 
Instagram: instagram.com/plustherapeutics 
Twitter: twitter.com/plustxinc
Linkedin: linkedin.com/company/plustherapeutics

Genprex, reprogramming the course of cancer and diabetes

Genprex, reprogramming the course of cancer and diabetes

December 8, 2020

 

rodney_varner_headshot.jpg

 

Rodney Varner, the CEO of Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes joins eHealth Radio and the Cancer Information Diabetes and Health News Channels.


Listen to interview with host Eric Michaels and guest Rodney Varner discuss the following:

  1. What inspires you at Genprex?
  2. Please give us an overview of Genprex’s gene therapies in development. What is it intended to treat, and how does it work?
  3. Could you talk more specifically about Genprex’s lead product candidate GPX-001?
  4. Could you please give us some insight about GPX-002, gene therapy for people with diabetes and what is it comprised of?
  5. What are the benefits of Genprex’s targeted therapies for people with non-small cell lung cancer?

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.

 

Genprex_LOGObu36u.png

 

Website: genprex.com

Social Media Links:
Facebook: facebook.com/genprexinc 
Linkedin: linkedin.com/company/genprex 
Twitter: twitter.com/genprex

Citius Pharmaceuticals, dedicated to the development and commercialization of critical care products

Citius Pharmaceuticals, dedicated to the development and commercialization of critical care products

December 5, 2020

 

Citius_Pharma_Feature-27ir8u.png

Myron Holubiak, President and CEO of Citius Pharmaceuticals, and Leonard Mazur, Chairman of the Board at Citius Pharmaceuticals, a specialty late-stage pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives and cancer care joins eHealth Radio and the Cancer Information and Health News Channels.


Listen to interview with host Eric Michaels and guests Myron Holubiak & Leonard Mazur discuss the following:

  1. Please give us an overview of catheter-related bloodstream infections (CRBSIs) and central venous catheters (CVCs).
  2. Who is at Risk for Catheter-Related Bloodstream Infections (CRBSIs)?
  3. Please give us a brief description of Minolok and how does it help the standard of care in the management of CRBSIs?
  4. Give us a brief description of our NoveCite subsidiary and the impact of Covid 19 patients w ARDS. What is your technology and why is it different?
  5. How is the development of MinoWrap for mastectomies progressing after your collaboration w MD Andersen?
  6. Why did the both of you invest 26.5 million into the company?

Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC (“Akrimax”), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008, and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur also co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC (“Triax”), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder, and, from 1995 to 2005, Chief Executive Officer, of Genesis Pharmaceuticals, Inc. (“Genesis”), a dermatological products company that marketed its products through dermatologists’ offices, and co-promoted products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company.

Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation, as Executive Vice President, ICN Pharmaceuticals, Inc., as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.

Mr. Mazur is a member of the Board of Trustees of Manor College, and is a recipient of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from Temple University, and has served in the US Marine Corps Reserves.


Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was co-founder, director and CEO of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. Mr. Holubiak was the President of Roche Laboratories, Inc. (“Roche”), a major research-based pharmaceutical company, from December 1998 to August 2001.

Prior to that, he held sales and marketing positions at Roche during his 19-year tenure there. As President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company. He was also founder of Emron, Inc., a health economics and managed care consulting company, and helped to create the Academy of Managed Care Pharmacy (AMCP). Mr. Holubiak was also a director of Bioscrip, Inc., a national home infusion company, from 2002 through 2016, and served as its Chairman of the Board from 2012 through 2016.

Since July 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. (“Assembly”) and its predecessor, Ventrus Biosciences, Inc. Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation. He received a BS in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London, as well as advanced training in health economics from the University of York’s Centre for Health Economics.

 

300_colorCITIUS-PHARMA-LOGO-WIDE.png

 

Website: citiuspharma.com

Oncotarget Podcast Named Among Top-ten Open-access Podcasts of 2020

Oncotarget Podcast Named Among Top-ten Open-access Podcasts of 2020

May 2, 2020

 

oncotarget-logo-square.jpeg

 

Mr. Ryan James Jessup, the Director of External & Legal Affairs for Impact Journals, the publishing house of Oncotarget joins eHealth Radio and the Health News Channel.


Listen to interview with host Eric Michaels and guest Ryan James Jessup discuss the following:

  1. Oncotarget was just recently named in the top ten open-access podcasts for 2020 by player.fm?
  2. Tell us a little about Oncotarget if you would.
  3. Now how do you distinguish Oncotarget’s podcast from every other cancer podcast out there?
  4. Oncotarget has been the largest cancer research journal for half a decade...talk to us more in that regard.

Oncotarget (a primarily oncology-focused, peer-reviewed, open access, weekly journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial Introducing OncoTarget.

 

 oncotarget-logo-square.jpeg

 

Website: www.Oncotarget.com

Social Media Links:
Twitter: www.twitter.com/oncotarget 
Facebook: www.facebook.com/oncotarget

Shifting the Melanoma Detection Landscape

Shifting the Melanoma Detection Landscape

April 24, 2020

 

jdobak-headshotDMTK.jpg

 

Dr. John Dobak, the President & CEO of DermTech, the leading genomics company in dermatology that is creating a new category of medicine, precision dermatology, enabled their non-invasive skin genomics platform joins eHealth Radio and the Dermatology and Health News Channels.


Listen to interview with host Eric Michaels and guest Dr. John Dobak discuss the following:

  1. Precision medicine is a leading innovation. Can you tell us about Precision Dermatology and what that means?
  2. What is the value of genomics in dermatology?
  3. How does this non-invasive test have the potential to shift the melanoma detection landscape?
  4. How does the DermTech PLA work?
  5. Are you adapting to the shift towards tele-medicine within the current environment? 6. What is next for DermTech? Are there other applications of this technology?

Dr. John Dobak, MD, has served as Founder and CEO of several venture-backed life science companies in San Diego. Dr. Dobak is the President of the JAKK Group, a life sciences technology accelerator, which has created several companies, including Lithera, INNERCOOL Therapies, and CryoGen/CryoCor. These companies have developed and marketed therapeutics, ranging from endovascular hypothermia to treat cardiac arrest to catheter-based treatments for cardiac arrhythmias. They have been financed by top tier investment firms and have achieved exits through acquisition and an IPO. Dr. Dobak and these companies are the recipients of several awards for entrepreneurship and innovation, including UCSD Connect’s Most Innovative New Product and MIT’s TR 100. Dr. Dobak received a bachelor’s degree from UCLA and a medical doctorate from UCSD.

DermTech_Patch_Logo_Gray_WhiteBackground.jpg

Website: dermtech.com

Social Media Links:
Twitter: twitter.com/DermTech 
Instagram: instagram.com/dermtech 
Facebook: facebook.com/dermtech 
Linkedin: linkedin.com/company/dermtech

Platelet Activation and where it comes from

Platelet Activation and where it comes from

November 29, 2019

 

BillDubiel.png

 

Bill Dubiel, CEO of LightInterga Technologies maker of the ThromboLUX system, a simple 5-minute test that tells you the platelet activation status of a platelet bag, and lets you transfuse with confidence joins eHealth Radio and the Health News Channel.

 

Listen to interview with host Eric Michaels & guest Bill Dubiel discuss the following:

  1. What is platelet activation and what it the implication to transfusions?  
  2. Tell us about the platelet transfusion studies you have conducted and what the results show?
  3. How does the ThromboLUX test answer the question of platelet activation status? 
  4. Your studies suggest that by giving resting platelets to cancer patients they have better outcomes? Why?  
  5. Where does platelet activation come from and can it be prevented?
  6. Do you have any early users of the product and what could patients or medical professionals do to find out more about the technology?

Bill Dubiel is the President and CEO of LightIntegra Technologies, bringing more the 30 years of Healthcare experience with his last 10 years specifically helping medical device start-ups through the commercial buildout and product launch.

Previously, Bill was Chief Commercial Officer at PGDx and CyVek responsible for building a commercial organization to launch novel products into the global market. Bill also held executive sales, marketing, and service leadership positions at Ventana, Roche, Bayer and Chiron Diagnostics. Bill holds a BS from Rutgers University and an MBA from Phoenix University.


Websites: www.thrombolux.com  | www.lightintegra.com

Social Media Links:
Facebook: facebook.com/Thrombolux 
Twitter: @ThromboLUX

Transforming Lives with RNAi Technology

Transforming Lives with RNAi Technology

November 11, 2019

 

MichaelMolyneaux_FINAL.png

 

Dr. Michael Molyneaux, Chief Medical Officer of Sirnaomics, a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases joins eHealth Radio and the Cancer Information and Health News Channels.

 

Listen to interview with host Eric Michaels & guest Dr. Michael Molyneaux discuss the following:

  1. Can you tell us about your background?
  2. What is Sirnaomics? Can you provide us with a background of the company and its current disease indication focus?
  3. What are some available treatments for non-melanoma skin cancer?
  4. How are RNA-based therapeutics different than DNA-based medicine?
  5. What are some drawbacks to RNAi-based therapy?
  6. What is Sirnaomics doing to address these challenges?
  7. What should people keep in mind when thinking about cancer treatment?

Dr. Michael Molyneaux, M.D., MBA & Chief Medical Officer of Sirnaomics brings a unique background with 20 years of experience in clinical medicine and direct patient care combined with 15 years of experience in clinical trial development. Mike is a board certified Medical Doctor and has completed his MBA. He was previously the CMO of Macrocure, a late stage clinical company that completed successful IPO in fall of 2014. Mike’s role is to help define therapeutic programs that will match the key properties of our lead product candidates. He is responsible for Global Clinical Operations, Regulatory Affairs, and Medical Affairs. Mike is also a member of the Sirnaomics Board of Directors.

 

Sirnaomics_LOGO.jpg

Website: https://sirnaomics.com

Social Media Links:
LinkedIn: linkedin.com/company/sirnaomics-inc 
Facebook: facebook.com/sirnaomics

Harnessing the Immune System to Fight Cancer

Harnessing the Immune System to Fight Cancer

October 4, 2019

 

Bellicum_Rick_Fair_Headshot.jpg

 

Rick Fair, President & CEO of Bellicum Pharmaceuticals, a biopharmaceutical company working to develop innovative treatments for cancer that are more effective and safer than standard chemotherapy and radiation treatment joins eHealth Radio & the Cancer Information and Health News Channels.

 

Listen to interview with host Eric Michaels & guest Rick Fair discuss the following:

  1. How does CAR-T cancer therapy compare to standard cancer treatments?
  2. What are some of the drawbacks to CAR-T Therapy?
  3. What is Bellicum doing to address these challenges?
  4. What should people keep in mind when thinking about cancer treatment?

Rick Fair is the President and CEO of Bellicum Pharmaceuticals, a biopharmaceutical company working to develop innovative treatments for cancer that are more effective and safer than standard chemotherapy and radiation treatment.

Prior to joining Bellicum, Mr. Fair served as the Senior Vice President, Head of Oncology Global Product Strategy at Genentech/Roche, where he led oncology product strategy and global commercialization. He also oversaw the global launch of five new cancer treatments, including TECENTRIQ®, the first immunotherapy approval for patients with advanced bladder cancer and contributed to a substantial expansion of investment into cancer immunotherapy and precision medicine.

Prior to Genentech, Mr. Fair spent nine years at Johnson & Johnson, where he held leadership roles in marketing, managed care and reimbursement strategy, and managed care customer management. Mr. Fair received his B.S. from the University of Michigan and his M.B.A. from Columbia Business School.

 

BellicumPharmaceuticals_LOGO.png

 

Website: bellicum.com

Social Media Links:
Facebook: facebook.com/pages/Bellicum-Pharmaceuticals-Inc
Twitter: @BellicumPharma

One Woman’s Spiritual Journey: A Model for Anyone Seeking Unlimited Love and Strength

One Woman’s Spiritual Journey: A Model for Anyone Seeking Unlimited Love and Strength

December 30, 2018

 

VivianneNantel.jpg

 

Vivianne Nantel is a 21st century mystic and spiritual guide who overcame an abusive childhood, deep depression, advanced cancer and even a brush with death by harnessing the power of yoga and her own spiritual energy joins eHealth Radio and the Personal Development Channel. Vivianne is the author of: Becoming the Light: Realize Your True Enlightened Nature.

 

Listen to interview with host Eric Michaels and guest Vivianne Nantel discuss the following:

  1. What inspired you to write this book?
  2. Can you talk about your experience with advanced breast cancer, and how you used your own mind, body, and spirit to fight it?
  3. Please talk about some of the most profound moments you experienced on your journey. How did they stay with you, and influence you?
  4. How can this book help people suffering from chronic problems, such as depression or anxiety?

Vivianne Nantel is the real deal: a 21st century mystic and spiritual guide who overcame an abusive childhood, deep depression, advanced cancer and even a brush with death by harnessing the power of yoga and her own spiritual energy. She has been with Sadhguru, the Dalai Lama, Sri Sri Ravi Shankar and Yogiraj Gurunath, and became a gifted teacher of her own.

Her new book, Becoming the Light: Realize Your True Enlightened Nature (Greenleaf Book Group Press, August 2018), chronicles her incredible story. Based in California, she’s also a humanitarian, speaker, animal advocate, vocalist and also has appeared on on various television talk shows, including Earth Advocate and Bridging Heaven and Earth.

 

BecomingtheLight_COVER.jpg

 

Website: viviannenantel.com

Social Media Links:
Facebook: https://www.facebook.com/VivianneNantel
Instagram: https://www.instagram.com/viviannenantel
Twitter: https://twitter.com/VivianneNantel1


The views, ideas, thoughts and opinions expressed on any program are those of the persons appearing on the program and do not necessarily reflect the views and opinions of the eHealth Radio Network.

Financial toxicity’s devastating effect on people with late stage illnesses – there are solutions.

Financial toxicity’s devastating effect on people with late stage illnesses – there are solutions.

November 1, 2018

 

AdamBalinksy.jpg

 

Adam Balinsky, Founder and President of Fifth Season Financial, a financial services firm which offers solutions and products to help relieve the financial pressures faced by many patients struggling with advanced illnesses, including cancer joins eHealth Radio and the Health News Channel. Its FLAG (Funds for Living and Giving) program is designed to bridge the gap between the traditional financial assistance programs available to mitigate the direct medical and treatment costs, and the much broader financial needs of patients.

 

Listen to interview with host Eric Michaels & guest Adam Balinsky discuss the following:

  1. What is financial toxicity and how does it impact your clients?
  2. What’s the difference between your FLAG program and viatical settlements?
  3. Why aren’t nonprofits and hospitals talking about this option when it comes to people who are dealing with late stage illnesses?
  4. Is there a personal story behind FSF that you can share?
  5. What’s the thing your most proud of when it comes to your business?

 

Adam Balinsky is the Founder and President of Fifth Season Financial. He passionately believes in the mission of the company—to help relieve the financial pressures faced by many patients struggling with advanced illnesses including cancer.

Adam recognizes that people facing advanced-stage diseases have incremental financial pressures affecting everyday life that are not being addressed. That’s why Fifth Season’s financial assistance program, FLAG (Funds for Living and Giving), is designed to bridge the gap between the traditional financial assistance programs available to mitigate the direct medical and treatment costs, and the much broader financial needs of patients. The FLAG Program provides patients with money from a non-traditional asset – their existing life insurance policy.

Adam hopes that those who use our financial assistance program are able to use the funds to maintain or better their quality of life. The funds can be used as the patient sees fit. Common uses include paying rent or mortgage bills, utility bills, medication costs, treatment costs. Others use the funds to take a dream trip—creating lasting memories with family members, to pay for in-home care, or to pay to bring family together. To date, Fifth Season has assisted nearly 400 patients and their families and provided more than $75 million in financial help to patients with advanced illnesses.

The Story Behind Adam’s Passion for Fifth Season’s Services

A year after Adam and his family moved to the United States from Canada, his wife, Tracey, was diagnosed with breast cancer. While dealing with the sobering realities of their new situation, Adam began to learn about the many ways organizations in the U.S. support patients medically and emotionally. However, he was disappointed to see the very limited structured support for the broad range of financial strains patients often face. Adam was motivated and inspired to proactively do something about it. After serving as director of Fifth Season Financial from 2007 through 2009, Adam acquired Fifth Season Financial in October 2012. He then structured and developed the FLAG program to specifically address financial needs of people facing advanced-stage illnesses. Beyond Fifth Season, Adam and Tracey (who is now five years post treatment and doing very well!) are very active in supporting cancer causes, including Gilda’s Club Westchester, where Tracey is a member of the Board of Directors.

Adam’s Expertise

Adam is a lawyer by training, having practiced law for 11 years at Baker & McKenzie LLP, where he became a partner in 2005. Adam holds a joint MBA/JD from the University of Toronto and a Bachelors of Commerce from McGill University. He is admitted to practice law in the Province of Ontario, Canada, and is in good standing with the American Bar Association and the Law Society of Upper Canada. He has served on the Board of Directors of the Life Insurance Settlement Association (LISA) from May 2011 to May 2013.

 

Fifth_Season_Logo.jpg

 

Website: www.fifthseasonfinancial.com

Social Media Links:
Facebook: facebook.com/5SeasonFin
Twitter: @5SeasonFin
LinkedIn: linkedin.com/company/fifth-season-financial-assistance

Podbean App

Play this podcast on Podbean App